Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
Publishing timestamp: 2023-11-02 08:24:16
Summary
Novo Nordisk's weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months. The drug has shown promising results in reducing the risk of cardiovascular disease. The approval could potentially boost insurance coverage prospects for the drug. Novo Nordisk also reported record profits and sales for the period. However, supply shortages may continue to hamper the rollout of the drug.
Sentiment: POSITIVE
Tickers: NOVO.B-DK,
Keywords: business news, business, biotech and pharmaceuticals, biotechnology, novo nordisk a/s, pharmaceuticals,